In the randomized clinical trial of trastuzumab CT-P6, the incidence of AEs in patients with HER2-positive breast cancer was comparable between CT-P6 and reference trastuzumab (94% and 95%), while the most commonly reported serious AEs were febrile neutropenia and neutropenia [30]. Here, ERBB2 is linked to neutropenia.